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Carcinoid heart disease (CHD) occurs in 20–70% of the patients with metastatic well-differentiated neuroendocrine tumours (NET).
We evaluated whether natriuretic peptides (ANP or NT-proBNP) are useful in early detection of CHD. Blood samples from 32
patients with NET were compared with cardiac ultrasound follow-up. CHD was defined as thickening of the tricuspid valve in the
presence of grade III–IV/IV tricuspid valve regurgitation. CHD was found in nine out of 32 patients (28%), all with symptoms of the
carcinoid syndrome compared to 65% in the 23 patients without CHD (P¼0.04). Median levels of NT-proBNP and 5-HIAA were
significantly higher in patients with CHD (894ngl
 1 and 815mmol24h
 1) compared to those without (89 and 206ngl
 1, Po0.001
and P¼0.007). No significant differences were detected in ANP levels (P¼0.11). Dilatation of the right atrium and ventricle as well
as thickening of the tricuspid valve and degree of regurgitation were statistically significant correlated with NT-proBNP levels. The
accuracy of NT-proBNP in the diagnosis of CHD was higher than that of ANP. A significantly better survival was observed in case of
normal NT-proBNP values. In conclusion, NT-proBNP is helpful as a simple marker in the diagnosis of CHD. Survival is better in
patients with normal levels of NT-proBNP.
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In 1981, De Bold et al (1981) first described the endocrine function
of the heart with natriuretic and diuretic effects. These hormonal
activities were later linked to peptides such as atrial natriuretic
peptide (ANP) and brain natriuretic peptide (BNP). The peptides
are produced primarily within the atria and ventricles of the heart
and are released into the circulation in response to increased wall
tension, thus reflecting increased intravascular volume. Both ANP
and BNP are produced as propolypeptides (pro-ANP and pro-
BNP) and are cleaved after excretion into the biological active
peptides (ANP and BNP) and an inactive N-terminal fragments
(NT-proANP and NT-proBNP). Both active and inactive peptides
can be isolated from the blood, but the stability of the
prohormones and NT-terminal fragments is much higher com-
pared to the activated form. After activation, natriuresis starts and
a decrease in blood pressure occurs as a result of shifting
intravascular fluid into the extravascular compartment and
suppression of the rennin–angiotensin–aldosteron axis.
Well-differentiated neuroendocrine tumours (NET) with liver
metastases can give symptoms of the characteristic carcinoid
syndrome with diarrhoea and flushes caused by the overproduc-
tion of serotonin. Carcinoid heart disease (CHD) is a well-known
complication of long-lasting exposure to high levels of serotonin
(Tornebrandt et al, 1986; Lundin et al, 1988; Robiolio et al, 1995;
Westberg et al, 2001; Zuetenhorst et al, 2003). Many carcinoid
patients die from cardiac causes (Ross and Roberts, 1985) and the
detection of CHD in an early stage is important to adjust therapy
and hence improve prognosis.
Large studies in the general population or in noncardiac patients
showed that measuring natriuretic peptides might be an effective
screening method for left-ventricular systolic dysfunction (McDo-
nagh et al, 1998; Luchner et al, 2000; Bay et al, 2003). In patients
with the suspicion of heart failure several other studies showed
natriuretic peptides to be useful indicators for the detection of
heart failure (Lerman et al, 1993; Davidson et al, 1996; Cowie et al,
1997; Hammerer-Lercher et al, 2001; Maisel et al, 2002, 2003). In
the follow-up of patients with an acute cardiac event levels of
natriuretic peptides were proved to be of prognostic value for
outcome (Hall et al, 1994; Omland et al, 1996; de Lemos et al, 2001;
Koglin et al, 2001; Richards et al, 2003).
Studies about the role of natriuretic peptides in patients with
NET are rare. In a report of Lundin et al (1989) ultrasound studies
were performed in 50 patients and combined with blood atrial
natriuretic peptide concentrations. In patients with clinical
findings of right ventricular failure significantly higher levels of
ANP were found. However, no studies have been performed to
determine the diagnostic value of BNP in patients with CHD.
In this study, we investigated the relationship between CHD and
the blood levels of NT-proBNP and ANP as markers for cardiac
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l(dys)function. We also examined survival of patients with and
without elevated levels of these natriuretic peptides in order to
evaluate the prognostic value of these hormones.
PATIENTS AND METHODS
Cardiac ultrasound studies were performed in 32 consecutive
patients with NET (18 women and 14 men) who visited the
outpatient department of the Netherlands Cancer Institute/Antoni
van Leeuwenhoek Hospital in 1999 and 2000 for follow-up. The
mean age was 61 years (range 34–77 years). The median interval
between the diagnosis of metastatic NET and the cardiac
investigation plus laboratory testing was 22 months (range 2–
121 months).
Cardiac ultrasound imaging
Two-dimensional echocardiography with continuous wave Dop-
pler and colour flow Doppler studies were performed using
standard techniques (Hewlett-Packard Sonos 5500 with 2.0/
2.5MHz probes). Echocardiographic parameters analysed were:
valve morphology (normal or thickened), valve mobility (normal,
mildly-, moderately-, severely diminished, fixed), valve regurgita-
tion (none, I–IV/IV), valvular stenosis and atrial/ventricular
dimensions. The criteria for CHD in our study was: a thickened
tricuspid valve with additional III/IV or IV/IV tricuspid valve
regurgitation (Zuetenhorst et al, 2003).
Laboratory techniques
Urinary 5-HIAA excretion and levels of NT-proBNP and ANP were
determined at the same time as the cardiac investigation. A routine
of 24h urine samples were collected and qualitatively evaluated for
5-HIAA and analysed by reversed-phase HPLC (normal
o40mmol24h
 1). A fluorescence detector was used for detection
and quantification (Stroomer et al, 1990).
Serum levels of NT-proBNP were determined in serum by an
electrochemiluminescence immunoassay used on the Modular
Analytics E170 (Roche Diagnostics, Mannheim, Germany). Normal
levels of NT-proBNP are affected by age (under or above 50 years)
and gender. According to instructions of the manufacturer, in
patients above 50 years the cutoff value for healthy women is
155ngl
 1 and for men 222ngl
 1. For practical reasons, we decided
to use a cutoff value of 200ngl
 1, because all our patients except
two were aged above 50 years. Atrial natriuretic peptide (ANP) was
measured in plasma samples using an IRMA assay manufactured
by CIS bio international, Gif-sur-Yvette, France (normal value
o43ngl
 1). Determination of NT-proBNP was performed in all
patients, ANP in 27 out of 32 patients (eight with CHD and 19
without CHD).
Chromogranin A levels were determined in serum using a solid-
phase two site immunoradiometric assay (normal o120mgl
 1).
Two monoclonal antibodies were prepared against sterically
remote sites on the CgA molecule. The first one is coated on the
tube and the second one, radiolabelled with iodine 125 is used as a
tracer (CIS bio international, Gif-sur-Yvette, France) (Degorce et al,
1999).
Histology
Histology was classified into low-grade (o10mitoses per 2mm
2
without necrosis) and high-grade neuroendocrine tumours
(410mitoses per 2mm
2 and/or necrosis) according to the revised
classification described by Capella et al (1995).
Statistics
Comparisons between the CHD and the non-CHD group were
made by the Mann–Whitney test or the Kruskal–Wallis test in
case of a continuous variable. Dichotomous variables were tested
by means of the Fisher’s exact test.
RESULTS
Tricuspid valvular lesions combined with regurgitation as
described in our criteria for CHD were found in nine out of 32
patients (28%). Additionally, severe dilatation of the right atrium
was present in almost all (eight out of nine) patients with CHD,
while severe dilatation of the right ventricle was found in three
non-CHD patients (Table 1).
In 29 out of 32 patients (91%) liver metastases were present. In
six patients urinary 5-HIAA excretion was normal, while it was
elevated in 26 patients (median 369mmol24h
 1, range 54-
1185mmol24h
 1). Patients with CHD had a significant longer
history of liver metastases compared to those without CHD
(median duration 40 and 14 months, respectively, P¼0.02)
(Table 2). All CHD patients suffered from the carcinoid syndrome
(flushes, diarrhoea or wheezing) compared to 65% of the non-CHD
patients (P¼0.04). No significant differences were seen between
the CHD and non-CHD group in respect to age, gender, presence
of liver metastases (Table 2).
During sample collection a total of 20 out of 32 patients were
treated with somatostatin analoga. Pharmacological doses of meta-
iodobenzylguanidine (MIBG) were administered in 18 patients,
two of them during sample collection. Nine patients received a
combination with radioactive labelled MIBG (Taal et al, 1996,
2000), all but one at least 3 months before blood collection. In all,
14 patients were treated with interferon, none of them during
collection time. There were no significant differences in these
treatment modalities between CHD and non-CHD patients.
111In-pentetreotide scintigraphy was available in 31 out of 32
patients. A positive scan was found in 26 out of 32 (81%) patients
and five patients had a negative scan. In four of these five patients,
the primary tumour was located in the midgut and in one patient
in the foregut.
Significantly higher median levels of NT-proBNP and urinary 5-
HIAA were found in the patients with CHD (894ngl
 1 and
815mmol24h
 1, respectively) compared to those without CHD (89
Table 1 Echocardiographic findings in carcinoid patients (n¼32)
according to the presence of heart disease
Without carcinoid
heart disease (n¼23)
Carcinoid heart
disease (n¼9)
a
Right atrium
Normal 21 (91%) 0 (0%)
Mildly dilated 2 (9%) 1 (11%)
Severely dilated 0 (0%) 8 (89%)
Right ventricle
Normal 22 (96%) 1 (11%)
Mildly dilated 1 (4%) 5 (56%)
Severely dilated 0 (0%) 3 (33%)
Tricuspid valve
Thickened 2 (9%) 9 (100%)
Normal 21 (91%) 0 (0%)
Tricuspid regurgitation
None 8 (35%) 0 (0%)
I/IV 8 (35%) 0 (0%)
II/IV 7 (30%) 0 (0%)
III/IV 0 (0%) 3 (33%)
IV/IV 0 (0%) 6 (67%)
aDefined as: thickening of the tricuspid valve with additional III/IV or IV/IV tricuspid
valve regurgitation.
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land 206ngl
 1; Po0.001 and P¼0.007, respectively) (Figure 1 and
Table 2). Median CgA levels were also found to be significantly
higher in patients with CHD (1958mgl
 1) compared with the non-
CHD group (684mgl
 1, P¼0.05). No significant differences were
detected in the levels of ANP between both groups (P¼0.11)
(Figure 1). Although levels of NT-proBNP are affected by age
(under or above 50 years) and gender, we applied a fixed cut-off
value of 200ngl
 1 because all our patients except two had an age
above 50 years. In two patients (both women) with an age under 50
years (34 and 47, respectively) the NT-proBNP levels were beneath
60ngl
 1. The advised cutoff value for this group is 155ngl
 1,
using our cutoff point of 200ngl
 1 did not make any difference in
our study population. For ANP, no differences in levels between
men and women are described and a correlation with age is weaker
than described in BNP (Clerico et al, 2002). The serum
concentration of NT-proBNP was elevated in all patients with
CHD. ANP levels were elevated in four out of seven CHD patients.
Elevated levels of NT-proBNP in patients with reported normal
echocardiographic findings were found in four out of 23 patients
(median 575ngl
 1, range 266–1449). In three of these patients
thickening of the tricuspid valve with grade II/IV tricuspid
regurgitation was already present. During follow-up 1 year later,
one of these patients met our criteria for CHD. The other two died
before a new echocardiography could be performed. The fourth
patient suffered from dilatation of the right atrium after a
myocardial infarction. NT-proBNP was elevated in all patients
with severe dilatation of either right atrium or ventricle and the
level of NT-proBNP was correlated with the degree of dilatation
(P¼0.002 and 0.005, respectively) (Figure 2) (Table 3). Elevated
NT-proBNP levels were found in four out of 21 patients with
normal dimensions of the right atrium (range 266–1449ngl
 1)
and in five out of 23 patients with normal right ventricle
dimension (range 266–2587ngl
 1). No significant correlation
was detected between the median levels of ANP and the existence
of atrial or ventricle dilatation (Table 3). Median NT-proBNP levels
were higher in patients with pathological thickening of the
tricuspid valve (894ngl
 1) compared to those with a normal
aspect of the tricuspid valve (84ngl
 1, Po0.001). Elevated levels of
NT-proBNP were present in all patients with severe tricuspid valve
regurgitation and significantly correlated with the degree of
regurgitation (P¼0.007). Such significant findings were not found
in the levels of ANP (Table 3).
Table 2 Clinical characteristics in carcinoid patients according to the presence of heart disease
Total group (n¼32)
Without carcinoid
heart disease (n¼23)
Carcinoid heart
disease
a (n¼9) P-value
Age at cardiac ultrasound (years)
Mean (range) 61 (34–77) 61 (34–76) 65 (51–77) 0.81
Sex
Male 14 (44%) 9 (39%) 5 (55%) 0.41
Female 18 (56%) 14 (61%) 4 (45%)
Duration of carcinoid disease at echocardiogram
(months)
Median (range) 22 (2–121) 20 (2–121) 40 (9–96) 0.08
Liver metastases 29 (91%) 21 (88%) 9 (100%) 0.36
Duration of liver metastases (months)
Median (range) 31 (2–96) 14 (2–84) 40 (9–96) 0.02
Symptoms of carcinoid syndrome
Yes 24 (76%) 15 (65%) 9 (100%) 0.04
No 8 (24%) 8 (35%) 0 (0%)
Primary tumour
Foregut 2 (6%) 2 (9%) 0 (0%) 0.16
Midgut 15 (47%) 11(48%) 4 (45%)
Hindgut 1 (3%) 0 (0%) 1 (10%)
Unknown 14 (44%) 10 (43%) 4 (45%)
Pathology
Low-grade NET
b 24 (76%) 16 (69%) 8 (90%) 0.33
High-grade NET 5 (16%) 5 (22%) 0 (0%)
Cytological function 3 (5%) 2 (9%) 1 (10%)
NT-proBNP (normal o200ngl
 1)
Median (range) 155 (23–4432) 89 (23–1449) 894 (328–4432) o0.001
ANP (normal o43ngl
 1)
Median (range) 26 (10–89) 25 (10–57) 41 (12–89) 0.11
5-HIAA (normal o40mmol(24h)
 1)
Median (range) 292 (19–1185) 206 (19–1116) 815 (87–1185) 0.007
CgA (normal o120mgl
 1)
Median (range) 777 (24–22282) 684 (24–9115) 1958 (506–22282) 0.05
aDefined as: thickening of the tricuspid valve with additional III/IV or IV/IV tricuspid valve regurgitation.
bNET¼neuroendocrine tumour.
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lIn our patient group NT-proBNP had a positive predictive value
(PPV) of 69% at a cutoff value of 200ngl
 1 and a negative
predictive value (NPV) of 100%. No additional information was
obtained by combining the NT-proBNP values with the ANP levels.
To determine the accuracy of both diagnostic tests, a receiver
operating characteristic (ROC) curve was used, which showed an
area under the curve for NT-proBNP of 0.94 (95% CI 0.85–1.04)
and for ANP of 0.69 (95% CI 0.44–0.96) (Figure 3). The highest
cutoff value of NT-proBNP with retaining a sensitivity of 100% was
300ngl
 1.
A significantly better survival was observed in patients with a
normal NT-proBNP value compared to those with elevated levels
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Figure 1 The median NT-proBNP serum level is significantly higher in
patients with CHD compared to those without. The difference in ANP
levels is not significant. Boxes are median and interquartiles range, whiskers
show ranges excluding outliers. Values beyond the lines are considered
outliers (þ).
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Figure 2 The median NT-proBNP serum level is significantly correlated
with the degree of dilatation of the right ventricle. Boxes are median and
interquartiles range, whiskers show ranges. Values beyond the lines are
considered outliers (þ).
Table 3 Levels of NT-proBNP and ANP according to the echocardio-
graphic findings
NT-proBNP level
(ngl
 1) (normal
o200ngl
 1)
ANP (ngl
 1)
(normal o43ngl
 1)
Carcinoid heart disease
Median (range)
Absent (n¼23) 89 (23–1449) 25 (10–57)
Present (n¼9) 894 (328–4432) 41 (12–89)
P-value Po0.001 P¼0.11
Right atrium dilatation
Median (range)
None (n¼21) 89 (23–1449) 26 (10–57)
Mildly dilated (n¼3) 195 (62–2587) 25 (20–30)
Severely dilated (n¼8) 738 (328–4432) 48 (12–89)
P-value P¼0.002 P¼0.36
Right ventricle dilatation
Median (range)
None (n¼23) 84 (23–2587) 25 (10–55)
Mildly dilated (n¼6) 407 (153–1058) 49 (12–62)
Severely dilated (n¼3) 1081 (581–4432) 52 (16–89)
P-value P¼0.005 P¼0.13
Tricuspid valve morphology
Median (range)
Normal (n¼21) 84 (23–372) 24 (10–57)
Thickened (n¼11) 894 (328–4432) 48 (12–89)
P-value Po0.001 P¼0.39
Tricuspid valve regurgitation
Median (range)
None (n¼8) 50 (23–1349) 18 (10–28)
Mild (I/IV & II/IV) (n¼15) 153 (52–1449) 26 (20–57)
Severe (III/IV &IV/IV)
(n¼9)
894 (328–4432) 41 (12–89)
P-value P¼0.007 P¼0.13
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l(P¼0.02). This difference was not seen in the group with a normal
compared to an elevated ANP level (P¼0.93) (Figure 4).
DISCUSSION
Thickening of the right heart valves caused by formation of fibrotic
plaques eventually followed by regurgitation and right ventricular
failure is a characteristic feature of CHD. In metastatic NET with
production of hormones the development of CHD is reported in
20–70% of the patients (Tornebrandt et al, 1986; Robiolio et al,
1995; Westberg et al, 2001; Zuetenhorst et al, 2003) and in many
patients attributed to the cause of death (Ross and Roberts, 1985).
In the present series of 32 patients, the incidence of CHD is 28%,
which is rather low compared to the results reported in literature.
This might be due to the strict criteria we used for the definition
CHD and the availability of octreotide the last decades has
improved survival in these patients group with probably a less
frequent development of CHD (Quaedvlieg et al, 2001).
In the follow-up and monitoring of carcinoid patients the
echocardiography is the cornerstone in the diagnosis of CHD.
However, performing an echocardiography is laborious, expensive
and not always readily available as referral to a cardiologist is
necessary. For these reasons, the cardiac evaluation of carcinoid
patients without symptoms of heart failure is often performed less
frequently than recommended. Clearly, a screening method
allowing rapid and accurate differentiation between patients with
and without CHD would be desirable. In this study with 32
patients, we found NT-proBNP to be a reliable marker to make this
differentiation with a sensitivity of 100% and a specificity of 83%.
This is comparable to the literature for diagnosis of cardiac
dysfunction in the general population (McDonagh et al, 1998;
Luchner et al, 2000) or in patients suspected to have heart failure
(Cowie et al, 1997; Maisel et al, 2002, 2003). The PPV of 69% as
described in our study is relatively high compared to studies in the
general population with a PPV of approximately 30% (Bay et al,
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Figure 3 The ROC curve shows that the accuracy to differentiate
between patients with and without heart disease is the best in NT-proBNP
compared to ANP levels.
P
r
o
b
a
b
i
l
i
t
y
60 50 40 30 20 10 0
1.2
1.0
0.7
0.8
0.9
0.6
0.5
0.4
0.3
Survival (months)
Elevated Censored
Not elevated Censored
P
r
o
b
a
b
i
l
i
t
y
60 50 40 30 20 10 0
1.2
1.0
0.8
0.6
0.4
0.2
Survival (months)
Elevated Censored
Not elevated Censored
Figure 4 Kaplan–Meier curves show a significant better survival in
patients with normal levels of NT-proBNP compared to those with
elevated levels. This does not apply for the levels of ANP.
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l2003), but is in accordance with studies performed in a population
with a higher chance of cardiac dysfunction (Cowie et al, 1997;
Hammerer-Lercher et al, 2001; Maisel et al, 2002). In our carcinoid
population, ANP was less reliable. An explanation could be the
application of the activated ANP, which is less stable compared to
the prohormone and NT-terminal fragment. However, earlier
reports did show diagnostic values for activated ANP in carcinoid
patients (Lundin et al, 1989; Zuetenhorst et al, 2003). Tested by a
ROC curve, the diagnostic capacities of NT-proBNP were better
compared to ANP, and no additional information was obtained by
combining NT-proBNP with ANP. Similar to our findings, in
earlier studies with a direct comparison between atrial and brain
natriuretic peptides, an advantage for brain natriuretic peptides
was convincingly proved with no increased predictive power by
addition of ANP to BNP determination (Davidson et al, 1996;
Cowie et al, 1997; McDonagh et al, 1998; Hammerer-Lercher et al,
2001).
Natriuretic peptides are mainly produced and excreted in the
atria of the heart in response to increased wall tension. BNP, in
contrast to ANP, is not only secreted from the atria, but also from
the ventricles, especially in patients with heart failure. Moreover,
there is a correlation between the degree of dilatation and levels of
natriuretic peptides (Yasue et al, 1994). Similar to the literature, we
also found a significant correlation between the levels of NT-
proBNP and the degree of dilatation of the right atrium and
ventricle. Although higher levels of ANP were detected in patients
with severe dilatation of the right atrium and ventricle compared
to those with only mild or no dilatation, this did not reach
significance. Most studies about the influence of cardiac dilatation
and levels of natriuretic peptides are performed in patients with
left-sided heart failure. Information about natriuretic peptide
excretion in right ventricular pressure overload, such as in CHD, is
scarce and therefore comparison of our findings with other studies
is difficult. In two studies of Tulevski et al() a relationship between
levels of ANP and BNP with right ventricular dysfunction was
reported. In our population, elevated levels of NT-proBNP were
present in all patients with severe tricuspid valve regurgitation and
a significant correlation between degree of regurgitation and NT-
proBNP levels was found.
Several studies described the prognostic value of natriuretic
peptides in patients with acute coronary syndromes and heart
failure (Omland et al, 1996; de Lemos et al, 2001; Koglin et al, 2001;
Richards et al, 2003). Patients with elevated levels of BNP were at a
higher risk of dying, developing heart failure or undergoing a new
myocardial event compared to those with normal levels. As might
be expected, we also found a significant better survival for patients
with normal levels of NT-proBNP compared to those with elevated
levels.
In conclusion, NT-proBNP is a reliable marker to make a rapid
and accurate differentiation between patients with and without
CHD. Survival of patients with normal levels of NT-proBNP is
better compared to those with elevated levels. As many patients
with hormonal active NET die from cardiac causes, the detection of
CHD in an early stage is important to adjust therapy and improve
prognosis. A regular screening of NT-proBNP levels might direct
the use of cardiac echography and guide treatment strategies.
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